

**FORMULARY Criteria for Using Fluvastatin or Fluvastatin XL and
NONFORMULARY Criteria for Using Pravastatin, Atorvastatin or Rosuvastatin in
Veteran Patients**

VHA Pharmacy Benefits Management Strategic Healthcare Group and the Medical Advisory Panel

These criteria are based on the best clinical evidence currently available. The recommendations in this document are dynamic, and will be revised as new clinical information becomes available. This guidance is intended to assist practitioners in providing consistent, high quality, cost effective drug therapy. These criteria are not intended to interfere with clinical judgment; the clinician must ultimately decide the course of therapy based on individual patient situations.

The Department of Veteran's Affairs National Formulary now includes 3 HMG Co-A Reductase Inhibitors (statins): 1) simvastatin (high potency-able to reduce LDL-C by 40% or more), 2) generic lovastatin, and 3) fluvastatin (both immediate and extended-release products) as an option for patients receiving potent inhibitors of CYP 3A4.

All of the available statins (lovastatin, simvastatin, fluvastatin, atorvastatin, pravastatin and rosuvastatin), when administered alone, have been associated with infrequent myotoxic adverse effects ranging from myalgia and myopathy to rhabdomyolysis.^{1,15} Factors that may increase the risk for myotoxicity with statins are higher dosages, drug-drug interactions, other myotoxic drugs (e.g. fibrates) and renal impairment.²⁻⁵

There is a lack of evidence to support a difference in the rate of myopathy or rhabdomyolysis for a particular statin when combined with fibrates and/or lipid lowering doses of niacin (≥ 1 gram/day). As a result, these criteria will focus on drug-drug interactions involving statins combined with drugs having the same metabolic pathway (e.g. CYP 3A4, 2C9, etc.).

The primary safety concern, in this case, stems from a drug-drug interaction occurring most commonly when potent CYP 3A4 inhibitors (e.g. macrolide antibiotics, azole antifungals, cyclosporine, protease inhibitors) are combined with CYP 3A4 metabolized statins (e.g. lovastatin, simvastatin or atorvastatin (nonformulary)). These drug combinations can increase blood levels of the affected statin and may further increase the risk of muscle toxicity. However, combination of these potent inhibitors with non-3A4 metabolized statins (e.g. fluvastatin, pravastatin (nonformulary) or rosuvastatin (nonformulary)) does not increase blood levels of these statins theoretically affording an additional margin of safety.

Fluvastatin is primarily metabolized via CYP 2C9 and may be vulnerable to interactions with drugs known to inhibit CYP 2C9 metabolism (e.g. amiodarone, omeprazole, metronidazole, fluvoxamine). However, many of these drug interactions with fluvastatin are only theoretical and their clinical significance is not known. In 2002, authors queried the Food and Drug Administrations (FDA) adverse event reporting system database to determine the number of reported cases of statin-associated rhabdomyolysis over a 29 month period (November 1997-March 2000). Of the 601 reported cases, fluvastatin was implicated in only 1.7% of cases and none of those cases involved the combination of fluvastatin with a CYP 2C9 inhibitor.⁶ Rosuvastatin is also metabolized via CYP 2C9 and may be vulnerable to interactions with drugs known to inhibit CYP 2C9 metabolism.¹⁵ As with fluvastatin, these interactions are only theoretical and the clinical significance is not known. Pravastatin is not significantly metabolized via the CYP isoenzyme system and is therefore not affected by drugs inhibiting metabolism via these pathways.^{1,7,8}

All patients receiving treatment with statins should be advised to report any unexplained muscle pain, tenderness or weakness regardless of statin used or concomitant drugs. Patients experiencing any of these symptoms should be advised to discontinue their lipid therapy immediately and providers should obtain a CK level as soon as possible, if clinically indicated.

There have been reports of excessive anticoagulation in patients receiving statins (lovastatin, simvastatin, fluvastatin, pravastatin and rosuvastatin) in combination with warfarin. As a result, the international normalized ratio (INR) should be monitored closely when statins are initiated or discontinued in patients stabilized on warfarin. These patients should also be warned to observe for signs of bleeding.^{14,15}

Formulary Criteria for Using Fluvastatin or Fluvastatin XL

1. Patients requiring statin therapy and long-term therapy with agents known to be potent inhibitors of CYP 3A4 including but not limited to: clarithromycin, erythromycin, cyclosporine, protease inhibitors (except nelfinavir), delavirdine, itraconazole, fluconazole, ketoconazole, and nefazodone. Patients taking nelfinavir should not be switched from pravastatin to fluvastatin (see nonformulary criterion number 1 for pravastatin).
2. Patients receiving lovastatin or simvastatin, requiring short-term treatment with a potent CYP 3A4 inhibitor, should have their statin temporarily withheld or closely monitored during their course of therapy. In general, there is no need to switch to fluvastatin in these patients unless the course of CYP 3A4 inhibitor therapy becomes prolonged.
3. Patients experiencing muscle pain or weakness, without elevation in creatine kinase (CK), on formulary statins (simvastatin or lovastatin) may receive a trial of fluvastatin with close follow up.

Nonformulary Criteria for Using Pravastatin in Place of Simvastatin, Lovastatin or Fluvastatin

1. Patients receiving nelfinavir. (The active metabolite of nelfinavir is formed via CYP 2C19.⁹ It has been postulated that since fluvastatin is both a substrate and an inhibitor of CYP 2C9, it may lower the concentration of the active metabolite of nelfinavir. However, in a small study of 16 patients receiving fluvastatin or placebo in combination with protease inhibitors, serum concentrations of nelfinavir and ritonavir were measured as markers for drug interactions. The authors concluded that there were no apparent interactions with these protease inhibitors and fluvastatin.¹⁰)
2. Those patients not achieving their LDL-C goals on the maximum dose of fluvastatin and requiring the use of a non-CYP 3A4 metabolized statin based upon the criteria for using fluvastatin or fluvastatin XL.
3. Patients experiencing muscle pain or weakness, without elevation in creatine kinase (CK), on fluvastatin and receiving potent CYP 3A4 inhibitors may receive a trial of pravastatin with close follow up.

Nonformulary Criteria for Using Atorvastatin in Place of Lovastatin, Simvastatin or Fluvastatin

1. Inadequate LDL-C lowering response to maximum dose simvastatin or maximally tolerated doses of simvastatin in patients not receiving potent CYP 3A4 inhibitors.

Nonformulary Criteria for Using Rosuvastatin in Place of Lovastatin, Simvastatin or Fluvastatin

1. Inadequate LDL-C lowering response to maximum dose fluvastatin or pravastatin (nonformulary) in patients receiving potent CYP 3A4 inhibitors. The initial dose in these patients should be 5 mg daily.
2. Rosuvastatin can be considered in those patients not meeting their LDL-C goals on maximum doses or maximally tolerated doses of simvastatin.
3. The VA Medical Advisory Panel (MAP) has recommended that rosuvastatin 20 mg daily generally be the maximum daily dose of rosuvastatin in the veteran population until more safety data are available for the 40 mg dose. However, the 40 mg dose can be considered only after confirmation of compliance with the lipid-lowering regimen; after a careful assessment of the benefits and risks in an individual patient; and only if the patient has not met their LDL-C goal (VA/DoD Dyslipidemia Guideline) on 20 mg daily. Factors that can increase the risk for serious adverse events (myopathy and rhabdomyolysis) should be considered in the risk assessment. These factors include but are not limited to: increasing statin doses, drug-drug interactions, hypothyroidism, frailty, advanced age and renal impairment. In those patients on rosuvastatin 40 mg daily, the MAP recommends baseline and periodic urinary and renal function monitoring. If unexplained, persistent proteinuria is noted in a patient receiving rosuvastatin 40 mg daily, the manufacturer recommends reducing the dose of rosuvastatin.
4. Rosuvastatin is not a substrate for cytochrome P450 3A4 (CYP 3A4) and therefore is not vulnerable to interactions with potent CYP 3A4 inhibitors. However, there are other interactions and situations that can result in clinically significant increases in rosuvastatin's serum concentrations. As a result, the manufacturer has recommended dose limits or dosing guidance for rosuvastatin in these individuals (e.g. cyclosporine, gemfibrozil, antacids, severe renal impairment, hemodialysis, Asian Americans). See table below on page 3.

Rosuvastatin Dosing in Special Circumstances*

Special Circumstance	Starting Daily Dose	Maximum Daily Dose
Those predisposed to myopathy (advanced age, renal impairment, hypothyroidism)	5 mg	20 mg
Severe renal impairment (crcl<30 ml/min)	5 mg	10 mg
Hemodialysis recipients	5 mg	5 mg
Combined with cyclosporine	5 mg	5 mg
Combined with gemfibrozil	5 mg	10 mg
Asians	5 mg	20 mg

*The VA Medical Advisory Panel (MAP) has recommended 20 mg to be the maximum daily dose of rosuvastatin in the veteran population until more safety data are available for the 40 mg daily dose. However, the 40 mg daily dose can be considered if a provider deems necessary. However, baseline and periodic urinary and renal function monitoring should be performed in these individuals.

Dose Conversion of Pravastatin to Fluvastatin, Metabolic Fate of Statins and Summary of Criteria

Approximate Equivalent Daily Doses of Statins: LDL-C Lowering Data from Clinical Trials. ¹¹						
	Lovastatin	Simvastatin	Fluvastatin	Pravastatin	Atorvastatin	Rosuvastatin
	20 mg	10 mg	40 mg	20 mg	--	--
	40 mg	20 mg	80 mg	40 mg	10 mg	--
	80 mg	40 mg	--	**	20 mg	--
	--	80 mg	--	--	40 mg	10 mg
	--	--	--	--	80 mg	20 mg
Metabolic Fate:						
	Lovastatin	Simvastatin	Fluvastatin	Pravastatin	Atorvastatin	Rosuvastatin
Primary Metabolic Enzymes	CYP 3A4	CYP 3A4	CYP 2C9	Sulfation	CYP 3A4	CYP 2C9, 2C19
Lipophilicity	Lipophilic	Lipophilic	Hydrophilic	Hydrophilic	Lipophilic	Hydrophilic
Formulary Status of Statins						
	Lovastatin	Simvastatin	Fluvastatin	Pravastatin	Atorvastatin	Rosuvastatin
Formulary or Nonformulary	Formulary	Formulary	Formulary	Nonformulary	Nonformulary	Nonformulary
Recommendations For Using a Particular Statin			Those on potent CYP 3A4 inhibitors.*	Criteria for NF Use: Those receiving nelfinavir or those on potent CYP 3A4 inhibitors and having an inadequate LDL-C lowering response to fluvastatin.	Criteria for NF Use: Inadequate LDL-C lowering response to max dose simvastatin and not receiving potent CYP 3A4 inhibitors.	Criteria for NF Use: Inadequate LDL-C lowering response to max dose fluvastatin or pravastatin and receiving potent CYP 3A4 inhibitors. Initial dose in these patients should be 5 mg qd. Also in patients not meeting their LDL-C goals on formulary statins.
	Lovastatin	Simvastatin	Fluvastatin	Pravastatin	Atorvastatin	Rosuvastatin
Monthly Cost (\$) (30 day supply)	20 mg 8.70 40 mg 15.60 80 mg 31.20	10 mg 8.40 20 mg 10.50 40 mg 15.90 80 mg 21.60	20 mg 7.80 40 mg 9.90 80 mg XL 17.10	20 mg 26.40 40 mg 38.70 80 mg 61.20	10 mg 43.50 20 mg 65.10 40 mg 68.70 80 mg 64.80	5 mg 34.80 10 mg 34.80 20 mg 34.80 40 mg 34.80

**If a patient is receiving pravastatin 80 mg daily, conversion to fluvastatin XL 80 mg daily can produce similar reductions in LDL-C (At 4 weeks, mean change in LDL-C was 37% for pravastatin 80 mg vs. median LDL-C change of 38% for fluvastatin XL 80 mg).¹²⁻¹³

Immediate release fluvastatin should be used only in doses of 20 or 40 mg daily. In those patients requiring 80 mg daily, conversion to fluvastatin XL is recommended. *Prices are as of 8-22-06 and do not consider tablet splitting.

*Potent CYP 3A4 inhibitors include but are not limited to: azole antifungals (fluconazole, ketoconazole, itraconazole), macrolides (erythromycin and clarithromycin), protease inhibitors, delavirdine, cyclosporine and nefazodone.

For more detailed information on statins refer to the following website:

<http://www.pbm.va.gov/reviews/HMGStatins04-09-03.pdf> . For more detailed information on rosuvastatin, refer to the following website: <http://vaww.pbm.va.gov/drugmonograph/Rosuvastatin.pdf>

Contact: Cathy Kelley, Pharm.D. (cathy.kelley@va.gov)

References

1. Bottorff M, Hansten P. Long-Term Safety of Hepatic Hydroxymethyl Glutaryl Coenzyme A Reductase Inhibitors. The Role of Metabolism-Monograph for Physicians. Arch Intern Med 2000;160:2273-2280.
2. Davidson MH, Stein EA, Dujovne CA, et al. The Efficacy and Six-Week Tolerability of Simvastatin 80 and 160 mg/day. Am J Cardiol 1997;79(1):38-42.
3. Ucar M, Mjorndal T, Dahlquist R. HMG-CoA Reductase Inhibitors and Myotoxicity. Drug Saf 2000;22(6):441-457.
4. Perault MC, Ladouch-Bures L, Dejean C, et al. Rhabdomyolysis During Pravastatin Treatment. Therapeu 1993;48:487.
5. Biesenback G, Janko O, Stuby U, et al. Myoglobinuric Renal Failure Due to Long-Standing Pravastatin Therapy in a Patient with Pre-existing Chronic Renal Insufficiency. Nephrol Dial Transplant 1996;11:2059-2060.
6. Omar MA, Wilson JP. FDA Adverse Event Reports on Statin-Associated Rhabdomyolysis. Ann Pharmacother 2002;36:288-295.
7. Beaird SL. HMG-CoA Reductase Inhibitors: Assessing Differences in Drug Interactions and Safety Profiles. J Am Pharm Assoc 2000;40:637-644.
8. Bays HE, Dujovne CA. Drug Interactions of Lipid-Altering Drugs. Drug Saf 1998;19(5):355-371.
9. Lillibridge JH, Lee CA, Pithavala YK, et al. The role of polymorphic CYP2C19 in the metabolism of nelfinavir mesylate [abstract 1156]. In Proceedings of the 5th International ISSX Meeting (Cairns, Australia). 1998.
10. Doser N, Kubli S, Telenti A, et al. Efficacy and safety of fluvastatin in hyperlipidemic protease inhibitor treated HIV-infected patients. AIDS 2002;16(14):1982-1983.
11. <http://www.pbm.va.gov/reviews/HMGStatins04-09-03.pdf>
12. Lescol/Lescol XL Product Information. Reliant/Novartis Pharmaceuticals. January 2001, East Hanover, NJ 07936.
13. Pravachol Product Information. Bristol-Myers Squibb. July 2001, Princeton, NJ 08543.
14. Williams D, Feely J. Pharmacokinetic-Pharmacodynamic Drug Interactions with HMG-CoA Reductase Inhibitors. Clin Pharmacokinet 2002;41(5):343-370.
15. Crestor Product Information. AstraZeneca Pharmaceuticals, August 2003. Wilmington, DE 19850